Cancer Translational Medicine最新文献

Cyclooxygenase-2 contributes to mutant epidermal growth factor receptor lung tumorigenesis by promoting an immunosuppressive environment 环氧化酶-2通过促进免疫抑制环境参与突变型表皮生长因子受体肺肿瘤的发生

Cancer Translational Medicine Pub Date : 2020-04-01 DOI: 10.4103/ctm.ctm_7_20

Mun‐kyoung Kim, A. Iravani, M. Topham

引用次数: 0

Characteristics and outcome of patients with pheochromocytoma 嗜铬细胞瘤患者的特点及预后

Cancer Translational Medicine Pub Date : 2020-04-01 DOI: 10.4103/ctm.ctm_5_20

Nadeema Rafiq, Tauseef Nabi, S. Dar, Shahnawaz Rasool

{"title":"Characteristics and outcome of patients with pheochromocytoma","authors":"Nadeema Rafiq, Tauseef Nabi, S. Dar, Shahnawaz Rasool","doi":"10.4103/ctm.ctm_5_20","DOIUrl":"https://doi.org/10.4103/ctm.ctm_5_20","url":null,"abstract":"Aim: Pheochromocytomas are rare neuroendocrine tumors with variable clinical presentation, including hypertension, and usually arise from the adrenal medulla. The aim of the current study was to evaluate the clinical characteristics and therapeutic outcomes of patients with pheochromocytoma. Methods: This was a single-center retrospective observational study designed to study the clinical, laboratory, radiological, and surgical outcomes of 14 patients diagnosed with pheochromocytoma. Results: Of 14 patients, 10 were females and 4 males, with a mean age of 38 ± 16 years at diagnosis. Headache (96.6%), palpitation (64.3%), abdominal pain (64.3%), and sweating (57.1%) were the most common presenting symptoms, while triad was present in 42.8%. Hypertension was the predominant clinical finding (92.8%) followed by orthostasis in 35.7% and hyperglycemia in 35.7%. Most pheochromocytomas were sporadic (85.7%), adrenal gland tumors (78.6%), and benign (92.8%); two were familial (each due to neurofibromatosis type and von Hippel–Lindau). Metanephrine and nor-metanephrine secretory pattern was seen in 58.3% of the patients, while metanephrine only was seen in 41.7% of the patients. More than half of the tumors (54.5%) were located on the left side, with 36.4% on the right side, and one patient had bilateral presentation of a tumor. Postsurgical remission of hypertension was found in 35.7% of the hypertensive patients. Biochemical cure was obtained in 85.7% and surgical cure rate in 78.5% of the patients. Patient survival ranged from 2 months to 9 years. Conclusions: The present study confirms that the clinical presentation of pheochromocytoma is variable and nonspecific. Although pheochromocytoma is a rare tumor, proper evaluation, preoperative preparation, and complete surgical excision are important for its management.","PeriodicalId":9428,"journal":{"name":"Cancer Translational Medicine","volume":"73 1","pages":"25 - 29"},"PeriodicalIF":0.0,"publicationDate":"2020-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83935989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparison of histopathological grading and staging of breast cancer with p53-positive and transforming growth factor-beta receptor 2-negative immunohistochemical marker expression cases p53阳性和转化生长因子-受体2阴性免疫组化标志物表达乳腺癌组织病理学分级和分期的比较

Cancer Translational Medicine Pub Date : 2020-04-01 DOI: 10.4103/ctm.ctm_4_20

P. Mandal, Anindya Adhikari, Subir Biswas, A. Giri, Arnab Gupta, A. Bhattacharya

{"title":"Comparison of histopathological grading and staging of breast cancer with p53-positive and transforming growth factor-beta receptor 2-negative immunohistochemical marker expression cases","authors":"P. Mandal, Anindya Adhikari, Subir Biswas, A. Giri, Arnab Gupta, A. Bhattacharya","doi":"10.4103/ctm.ctm_4_20","DOIUrl":"https://doi.org/10.4103/ctm.ctm_4_20","url":null,"abstract":"Background: Immunohistochemical analysis of biomarkers is essential to understand the nature of breast cancer (BC) and predict its prognosis. A noticeable correlation is found between p53-positive and transforming growth factor-beta receptor 2 (TGFBR-2)-negative immunomarker expression in BC cases. Materials and Methods: Between January 2018 and December 2018, immunohistochemical analysis of p53 and TGFBR-2 biomarkers was done in biopsy samples from 50 BC cases (49 females and 1 male). Results: p53 expression was positive in 24 (48%) and negative in 26 (52%) cases. Similarly, TGFBR-2 expression was positive in 26 (52%) and negative in 24 (48%) cases. Among p53-positive cases, 8 (16%), 15 (30%), and 1 (2%) cases correlated with histologic Grade 1, Grade 2, and Grade 3 cases, respectively. Among TGFBR-2-negative cases, 9 (18%), 13 (26%), and 2 (4%) cases correlated with histologic Grade 1, Grade 2, and Grade 3 cases, respectively. Further, Grade 2 cancer cases were found mostly associated with both p53-positive and TGFBR-2-negative cases. Maximum p53positive cases was in T2N1Mx stage while maximum TGFBR-2-negative cases were in T2N0Mx stage. Conclusion: p53-positive and TGFBR-2-negative cases are mostly associated with Grade 2 and T2 stage of BC.","PeriodicalId":9428,"journal":{"name":"Cancer Translational Medicine","volume":"1 1","pages":"30 - 33"},"PeriodicalIF":0.0,"publicationDate":"2020-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78972345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Chemical compositions and antiproliferative effect of essential oil of asafoetida on MCF7 human breast cancer cell line and female wistar rats 牛油果挥发油对MCF7人乳腺癌细胞系及雌性wistar大鼠的化学成分及抗增殖作用

Cancer Translational Medicine Pub Date : 2020-04-01 DOI: 10.4103/ctm.ctm_36_19

S. Bagheri, Davood Javidmehr, M. Ghaffari, Ehsan Ghoderti-Shatori

{"title":"Chemical compositions and antiproliferative effect of essential oil of asafoetida on MCF7 human breast cancer cell line and female wistar rats","authors":"S. Bagheri, Davood Javidmehr, M. Ghaffari, Ehsan Ghoderti-Shatori","doi":"10.4103/ctm.ctm_36_19","DOIUrl":"https://doi.org/10.4103/ctm.ctm_36_19","url":null,"abstract":"Background: Breast cancer is a leading cause of cancer-associated mortality in women, and the incidence is on the rise worldwide. Asafoetida has shown a good anti-cancer activity against breast cancer in both in vivo and in vitro studies. Materials and Methods: For the evaluation of the cytotoxic effect of essential oil of asafoetida (EOA), MCF7 cells, a highly invasive variant of human breast cancer cell line, were exposed to different concentrations of EOA (2, 4, 6, 8, and 10 μl/ml) over different periods (24, 48, and 72 h), followed by cell viability analysis using 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay. For determining thein vivo toxicity of EOA, the oil was administered orally at doses of 0.1, 1, 10, and 100 μl/kg for 28 days in female Wistar rats. After completion of the experiment, hematological and serum biochemical parameters were evaluated and compared to the untreated group. Results: MTT assay results showed that EOA significantly decreased the viability of MCF7 cells in a time- and concentration-dependent manner, demonstrating a strong cytotoxic effect of EOA on breast cancer cells. In chronic toxicity study, the female Wistar rats showed no change in hematological and biochemical parameters at any of the administered dose. Conclusions: The cytotoxic effect of EOA on breast cancer cells, without general toxicity, makes it a promising compound as adjuvant therapy for breast cancer.","PeriodicalId":9428,"journal":{"name":"Cancer Translational Medicine","volume":"52 1","pages":"34 - 39"},"PeriodicalIF":0.0,"publicationDate":"2020-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84088208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

Best-match blood transfusion in pediatric patients with mixed autoantibodies 混合自身抗体患儿的最佳配型输血

Cancer Translational Medicine Pub Date : 2020-01-01 DOI: 10.4103/ctm.ctm_27_19

Debasish Mishra, D. Sahoo, Smita Mahapatra, A. Panigrahi

引用次数: 1

Potential inhibitor for 2019-novel coronaviruses in drug development 2019新型冠状病毒药物开发中的潜在抑制剂

Cancer Translational Medicine Pub Date : 2020-01-01 DOI: 10.4103/ctm.ctm_3_20

Xiaohui Xu, Zi-long Dang, Lei Zhang, L. Zhuang, Wutang Jing, L. Ji, Guoyu Qiu

{"title":"Potential inhibitor for 2019-novel coronaviruses in drug development","authors":"Xiaohui Xu, Zi-long Dang, Lei Zhang, L. Zhuang, Wutang Jing, L. Ji, Guoyu Qiu","doi":"10.4103/ctm.ctm_3_20","DOIUrl":"https://doi.org/10.4103/ctm.ctm_3_20","url":null,"abstract":"The coronavirus disease 2019 (COVID-19), which is first detected in Wuhan, China, is a virus identified as the cause of pneumonia. In the event of epidemic outbreak, a series of actions have been taken by the Chinese government to control the pandemic of the virus, and effective medical methods are in urgent need to prevent COVID-19 infection and cure the disease, especially a drug that can suppress COVID-19 is urgently needed. However, there are no specific drugs and vaccine that can prevent coronavirus infection. Some research works on the transmissibility, severity, and other features associated with this virus are ongoing. Some works about new drug against COVID-19 are carried out; more time is required to develop an effective drug against pneumonia caused by COVID-19. Now, to develop broad-spectrum antiviral agents, there is a quick method to identify drugs with high binding capacity with COVID-19 by virtual screening based on the clinical drug libraries; all these drugs have been widely used in clinical applications with guaranteed safety, which may serve as promising candidates to treat the infection of COVID-19. In this article, we summarize the discovery and clinical application of specific drugs against COVID-19 as potential inhibitors to alleviate the current epidemic.","PeriodicalId":9428,"journal":{"name":"Cancer Translational Medicine","volume":"17 1","pages":"17 - 20"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74009985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

Clinicopathological association of p16 and its impact on outcome of chemoradiation in head-and-neck squamous cell cancer patients in North-East India p16的临床病理关联及其对印度东北部头颈部鳞状细胞癌患者放化疗结果的影响

Cancer Translational Medicine Pub Date : 2020-01-01 DOI: 10.4103/ctm.ctm_34_19

S. Mohanty, Y. Devi, Nithinraj Daniel, D. Ponna, M. Devi, L. Singh

{"title":"Clinicopathological association of p16 and its impact on outcome of chemoradiation in head-and-neck squamous cell cancer patients in North-East India","authors":"S. Mohanty, Y. Devi, Nithinraj Daniel, D. Ponna, M. Devi, L. Singh","doi":"10.4103/ctm.ctm_34_19","DOIUrl":"https://doi.org/10.4103/ctm.ctm_34_19","url":null,"abstract":"Purpose: Human papillomavirus-associated head–and-neck squamous cell cancer (HNSCC) is following an increasing trend in Western countries, which has unique biology and confers better prognosis, whereas there are limited data from Indian studies in this context. Methods: We conducted a prospective cohort study to evaluate the clinicopathological association of p16 in locally advanced HNSCC and its impact on outcome of chemoradiation. The study population was divided into two arms; p16-positive and p16-negative arms. All patients were treated with concurrent chemoradiation using weekly cisplatin. Statistical Analysis Used: SPSS version 21 for Windows was used for statistical analysis. Chi-square test and multivariate analysis were performed to evaluate different association and impact of p16. P <0.05 was considered statistically significant. Results: The present study found p16-positive HNSCC patients to be associated with better performance status (P = 0.010), oropharyngeal primary location (P = 0.034), advanced nodal stage at presentation (P = 0.000), and higher histopathologic grade of tumor (P = 0.021) and was associated with better response (P = 0.005) to concurrent chemoradiation. Subsite analysis revealed p16-positive oropharyngeal squamous cell cancer (OPSCC) to have significantly better response (P = 0.036) to chemoradiation, whereas a trend toward better response to chemoradiation (P = 0.066) was found among p16-positive non-OPSCC. Higher p16 expression score was associated with better (P = 0.000) response to chemoradiation. Multivariate analysis revealed p16 to have an independent positive impact on tumor response to chemoradiation in HNSCC irrespective of tumor subsite. Conclusion: p16 overexpression is a good prognostic factor in both OPSCC and non-OPSCC. Treatment response have a positive correlation with intensity of p16 staining in the tissue biopsy material.","PeriodicalId":9428,"journal":{"name":"Cancer Translational Medicine","volume":"6 1","pages":"10 - 16"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87006280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Protein disulfide isomerase A3: A potential regulatory factor of colon epithelial cells 蛋白二硫异构酶A3:结肠上皮细胞的潜在调节因子

Cancer Translational Medicine Pub Date : 2020-01-01 DOI: 10.4103/ctm.ctm_33_19

Yang Li, Z. Huang, Hai-ping Jiang

{"title":"Protein disulfide isomerase A3: A potential regulatory factor of colon epithelial cells","authors":"Yang Li, Z. Huang, Hai-ping Jiang","doi":"10.4103/ctm.ctm_33_19","DOIUrl":"https://doi.org/10.4103/ctm.ctm_33_19","url":null,"abstract":"Aim: This study aimed to investigate the effects of protein disulfide isomerase A3 (PDIA3) on the proliferation and apoptosis of colon epithelial cells, so as to explore its possible role in colon compensation of ultra-short bowel syndrome. Methods: The expression of PDIA3 gene in NCM460 colonic epithelial cells was upregulated and silenced by liposome transient transfection technique. The expression of PDIA3 protein was determined by Western blotting, the proliferation rate of NCM460 cells was detected by CCK8, and the apoptosis rate of NCM460 cells was determined by flow cytometry. Results: DNA sequencing and Western blotting results successfully verified that PDIA3 protein expression in NCM460 cells was upregulated and silenced by liposomal transfection. In the PDIA3 overexpression experiment, the proliferation rate of the experimental group was lower than that of the empty carrier group at 24 h, 48 h, and 72 h, and the apoptosis rate of the experimental group was higher than that of the empty carrier group (P < 0.05, the difference was statistically significant). In the PDIA3-silenced experiment, the proliferation rate of the experimental group was higher than that of the empty carrier group at 24 h, 48 h, and 72 h, and the apoptosis rate of the experimental group was lower than that of the empty carrier group (P < 0.05, the difference was statistically significant). Conclusion: PDIA3 inhibits the proliferation of human colonic epithelial cells (NCM460) and promotes their apoptosis, which may not be a key regulatory protein in colon compensation of ultra-short bowel syndrome.","PeriodicalId":9428,"journal":{"name":"Cancer Translational Medicine","volume":"39 1","pages":"1 - 9"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73847692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Supraclavicular lymphadenopathy as the initial manifestation in carcinoma of cervix 锁骨上淋巴结病是子宫颈癌的最初表现

Cancer Translational Medicine Pub Date : 2019-10-01 DOI: 10.4103/ctm.ctm_23_19

Priyanka Priyaarshini, T. Sahoo

引用次数: 0

ABO typing error resolution and transfusion support in a case of an acute leukemia patient showing loss of antigen expression ABO分型错误解决和输血支持在一例急性白血病患者显示抗原表达丧失

Cancer Translational Medicine Pub Date : 2019-10-01 DOI: 10.4103/ctm.ctm_28_19

Debasish Mishra, G. Ray, Smita Mahapatra, Pankaj Parida

引用次数: 0